Verve Therapeutics Dividend

Dividend criteria checks 0/6

Verve Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$2.38
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Apr 03

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 28

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Feb 13

Vectoring In On Verve Therapeutics

Jan 14

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Jun 07

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Feb 24

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

May 11

Verve Therapeutics: Early-Stage Biotech With A Large Market

Apr 16

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Jan 31

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Aug 24

Verve Therapeutics jumps 75% in its first day of trading

Jun 17

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if VERV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VERV's dividend payments have been increasing.

Dividend Yield vs Market

Verve Therapeutics Dividend Yield vs Market

How does VERV dividend yield compare to the market?
Segment	Dividend Yield
Company (VERV)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (VERV)	0%

Notable Dividend: Unable to evaluate VERV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VERV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate VERV's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as VERV has not reported any payouts.

Verve Therapeutics Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Verve Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Price target decreased by 20% to US$38.75

Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause

Verve Therapeutics, Inc. Announces Updates on its PCSK9 Program

Consensus revenue estimates increase by 86%

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Verve's Proof-Of-Concept Data Doesn't Inspire Confidence

Vectoring In On Verve Therapeutics

Verve Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Verve Therapeutics, Inc. has filed a Follow-on Equity Offering.

Verve Therapeutics, Inc. Presents Interim Data from Ongoing Heart-1 Phase 1B Clinical Trial of Verve-101

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Verve Therapeutics, Inc. Announces Clearance of Investigational New Drug Application by the U.S. Fda for Verve-101 in Patients with Heterozygous Familial Hypercholesterolemia

New minor risk - Share price stability

Verve Therapeutics, Inc. Announces Executive Changes

Price target increased by 9.8% to US$46.11

Consensus revenue estimates increase by 130%

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Consensus revenue estimates increase by 33%, EPS downgraded

Verve Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Insider exercised options to buy US$694k worth of stock.

Price target decreased to US$44.78

Price target decreased to US$48.75

High number of new directors

We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth

Verve Therapeutics Provides Regulatory Update on Verve-101 Investigational New Drug Application

Insider exercised options and sold US$384k worth of stock

Co-Founder exercised options and sold US$1.6m worth of stock

Insider exercised options and sold US$2.0m worth of stock

Verve Therapeutics, Inc. Announces Clearance of Clinical Trial Authorisation Application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for Verve-101 in Patients with Heterozygous Familial Hypercholesterolemia

Verve Therapeutics: Cathie Wood Adds To ARKK

President & COO exercised options to buy US$3.6m worth of stock.

Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate

Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate At the European Society of Cardiology 2022 Congress

High number of new directors

Co-Founder exercised options and sold US$1.4m worth of stock

Verve Therapeutics, Inc. Announces Board and Committee Changes

Verve Therapeutics, Inc. announced that it has received $34.999981 million in funding from Vertex Pharmaceuticals Incorporated

Verve Therapeutics, Inc. announced that it has received $34.999981 million in funding from Vertex Pharmaceuticals Incorporated

Verve Therapeutics falls postmarket on $200M stock offering

Insider notifies of intention to sell stock

More CRISPR In Human Subjects

Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia

Verve Therapeutics Appoints Alexander G. "Bo" Cumbo, to Its Board of Directors

Independent Chairman of the Board recently bought US$122k worth of stock

Verve Therapeutics, Inc. Announces Clearance of First VERVE-101 Clinical Trial Application

Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation

Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022

Verve Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Verve Therapeutics Presents Comprehensive Analyses of Off-Target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia

Verve Therapeutics: Early-Stage Biotech With A Large Market

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More Than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease

Key Executive recently bought US$86k worth of stock

Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans

Verve Therapeutics, Inc Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for Its Novel Base Editing Programs

Co-Founder exercised options and sold US$72k worth of stock

Co-Founder exercised options and sold US$4.3m worth of stock

Key Executive recently bought US$147k worth of stock

Verve Therapeutics, Inc. Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease

Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing

Verve Therapeutics, Inc. has completed an IPO in the amount of $266.679991 million.

Verve Therapeutics jumps 75% in its first day of trading

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies